Loading
A phase 3 trial of cetuximab, bevacizumab (glioblastoma use), fOLFOX (5-FU, leucovorin, oxaliplatin) and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by University of Campania Luigi Vanvitelli, now recruiting.
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT07389265 by University of Campania Luigi Vanvitelli, with a registry enrolment figure of 480 participants, started 2025-10-01 and due to reach its primary completion in 2030-10. Interventions recorded: Erbitux (Cetuximab); Bevacizumab; FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin); FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan). Conditions listed: Metastatic Colorectal Cancer (mCRC). Primary outcome: Overall Response Rate (ORR). Colorectal eligibility wording from the registry: "Histologically proven diagnosis of colorectal adenocarcinoma". Sites: Italy, Spain. No results are recorded here; the registry entry is the source.
Shares Bevacizumab (glioblastoma use), Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin) and the tag colorectal-deep-dive.